NCL

(redirected from Neuronal ceroid lipofuscinosis)
Also found in: Dictionary, Medical, Acronyms, Wikipedia.

NCL

GOST 7.67 Latin three-letter geocode for New Caledonia. The code is used for transactions to and from New Caledonian bank accounts and for international shipping to New Caledonia. As with all GOST 7.67 codes, it is used primarily in Cyrillic alphabets.
References in periodicals archive ?
Neuronal ceroid lipofuscinosis in Rambouillet sheep: characterization of the clinical disease.
Neuronal ceroid lipofuscinosis in a Vietnamese pot-bellied pig (Sus scrofa).
A missense mutation in ovine CLN6 causes neuronal ceroid lipofuscinosis in Merino sheep whereas affected South Hampshire sheep have reduced levels of CLN6 mRNA.
A mutation in canine CLN5 causes neuronal ceroid lipofuscinosis in border collie dogs.
Mutational analysis of the defective protease in classic late-infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disorder.
Two common mutations in the CLN2 gene underlie late infantile neuronal ceroid lipofuscinosis.
Tripeptidyl-peptidase I is apparently the CLN2 protein absent in classical late-infantile neuronal ceroid lipofuscinosis.
StemCells has completed a six patient Phase I clinical trial of its proprietary HuCNS-SC product candidate as a treatment for neuronal ceroid lipofuscinosis (NCL), a rare and fatal neurodegenerative disease that affects infants and young children.
The patient, a nine year old girl, was transplanted with HuCNS-SC cells in January 2007 as a participant in the Company's trial of HuCNS-SC cells as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL), a fatal neurodegenerative condition that affects infants and young children.
In January 2008, the Company completed enrollment and dosing of a six-patient Phase I clinical trial of its proprietary HuCNS-SC([R]) product candidate (purified human neural stem cells) as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL, also often referred to as Batten disease) at Oregon Health & Science University (OHSU) Doernbecher Children's Hospital.
In January 2008, we completed enrollment and dosing of a six-patient Phase I clinical trial of our HuCNS-SC([R]) product candidate (purified human neural stem cells) as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL, also often referred to as Batten disease) at Oregon Health & Science University (OHSU) Doernbecher Children's Hospital.
Full browser ?